Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug developed by the company [1] Group 1 - SHR-4610 injection has shown good anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] - The total research and development investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1]